Low-density lipoprotein receptor-related protein is decreased in optic neuropathy of Alzheimer disease

Journal of Neuro-Ophthalmology

Volumn 31, Issue 2, 2011, Pages 139-146

  Cuzzo, Lloyd M ^a   Ross Cisneros, Fred N ^a   Yee, Kenneth M ^a,b   Wang, Michelle Y ^a   Sadun, Alfredo A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b VMR Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; NEUROFILAMENT PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MICROVASCULATURE; NERVOUS TISSUE; OPTIC NERVE; OPTIC NERVE DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ASTROCYTES; AUTOPSY; CASE-CONTROL STUDIES; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; MIDDLE AGED; NEUROFILAMENT PROTEINS; OPTIC NERVE DISEASES;

EID: 79958037038     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0b013e31821b602c     Document Type: Article

References (57)

1. Alzheimer's Association. 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 2010;6:158-194.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60: 1119-1122. (Pubitemid 36975801)
3. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med. 1986; 315:485-487. (Pubitemid 16034149)
4. Sadun AA. The optic neuropathy of Alzheimer's disease. Metab Pediatr Syst Ophthalmol. 1989;12:64-68. (Pubitemid 19133562)
5. Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer's disease. Ophthalmology. 1990;97:9-17. (Pubitemid 20020620)
6. Danesh-Meyer HV, Birch H, Ku JY, Carroll S, Gamble G. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology. 2006;67: 1852-1854. (Pubitemid 44900767)
7. Syed AB, Armstrong RA, Smith CU. A quantitative analysis of optic nerve axons in elderly control subjects and patients with Alzheimer's disease. Folia Neuropathol. 2005;43:1-6. (Pubitemid 40533186)
8. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ. Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol. 1987;104:113-120. (Pubitemid 17119032)
9. Katz B, Rimmer S. Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol. 1989;34:31-43. (Pubitemid 19201303)
10. Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol. 2006;26:18-24. (Pubitemid 44502755)
11. Parisi V. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer's disease. Semin Ophthalmol. 2003;18:50-57. (Pubitemid 37108393)
12. Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest. 2002;110:1375-1381. (Pubitemid 35396905)
13. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356. (Pubitemid 34790756)
14. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545-555. (Pubitemid 40269768)
15. Rosenberg RN. The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. Neurology. 2000;54:2045-2054. (Pubitemid 30397200)
16. Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001;108:779-784. (Pubitemid 32880284)
17. Bell RD, Zlokovic BV. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009;118:103-113.
18. Zlokovic BV. New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics. 2008; 5:409-414. (Pubitemid 351952489)
19. Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2007;4:191-197. (Pubitemid 46562394)
20. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35:2628-2631. (Pubitemid 39458354)
21. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem. 2004;89:807-811. (Pubitemid 38684728)
22. Hyman BT, Strickland D, Rebeck GW. Role of the lowdensity lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. Arch Neurol. 2000;57: 646-650. (Pubitemid 30252798)
23. Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today. 2006;11:931-938.
24. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2009;8:16-30.
25. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res. 2003;61: 39-78. (Pubitemid 37187402)
26. DeMattos RB, Bales KR, Cummins DJ, Paul SM, HoltzmanDM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264-2267. (Pubitemid 34258840)
27. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron. 2004; 43:605-608. (Pubitemid 39179722)
28. Donahue JE, Flaherty SL, Johanson CE, Duncan JA III, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol. 2006; 112:405-415. (Pubitemid 44469161)
29. Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr Pharm Des. 2008;14: 1601-1605. (Pubitemid 352002987)
30. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, HoltzmanDM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489-1499. (Pubitemid 32038587)
31. Waldron E, Jaeger S, Pietrzik CU. Functional role of the lowdensity lipoprotein receptor-related protein in Alzheimer's disease. Neurodegener Dis. 2006;3:233-238. (Pubitemid 44600309)
32. Van Uden E,MalloryM, Veinbergs I, AlfordM, Rockenstein E, Masliah E. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci. 2002;22:9298-9304. (Pubitemid 35356173)
33. Quinn KA, Pye VJ, Dai YP, Chesterman CN, Owensby DA. Characterization of the soluble form of the low density lipoprotein receptor-related protein (LRP). Exp Cell Res. 1999;251:433-441. (Pubitemid 29431880)
34. Quinn KA, Grimsley PG, Dai YP, Tapner M, Chesterman CN, Owensby DA. Soluble low density lipoprotein receptorrelated protein (LRP) circulates in human plasma. J Biol Chem. 1997;272:23946-23951. (Pubitemid 27410977)
35. Tooyama I, Kawamata T, Akiyama H, Kimura H,Moestrup SK, Gliemann J,Matsuo A, McGeer PL. Subcellular localization of the low density lipoprotein receptor-related protein (alpha 2- macroglobulin receptor) in human brain. Brain Res. 1995; 691:235-238.
36. Williams SE, Kounnas MZ, Argraves KM, Argraves WS, Strickland DK. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and the receptor-associated protein. An overview. Ann N Y Acad Sci. 1994;737:1-13. (Pubitemid 24316254)
37. Wolf BB, Lopes MB, VandenBerg SR, Gonias SL. Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol. 1992;141:37-42.
38. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389-404. (Pubitemid 44469160)
39. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095-1097.
40. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41: 479-486.
41. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010;330:1774.
42. Wang MY, Ross-Cisneros FN, Aggarwal D, Liang CY, Sadun AA. Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer's disease. Acta Neuropathol. 2009;118:381-389.
43. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol. 1995;37:211-217.
44. Lopes MB, Bogaev CA, Gonias SL, VandenBerg SR. Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein is increased in reactive and neoplastic glial cells. FEBS Lett. 1994;338:301-305. (Pubitemid 2044676)
45. Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol. 1998; 10:667-671. (Pubitemid 28477027)
46. May P, Rohlmann A, Bock HH, Zurhove K, Marth JD, Schomburg ED, Noebels JL, Beffert U, Sweatt JD, Weeber EJ, Herz J. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol. 2004;24:8872-8883. (Pubitemid 39313893)
47. Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem. 2002;71:405-434. (Pubitemid 34800226)
48. Frosch M, Anthony DC, de Girolami U. Robbins and Cotran Pathologic Basis of Disease, 7th edition. Philadelphia, PA: Elsevier Saunders, 2005.
49. Pike CJ, Cummings BJ, Monzavi R, Cotman CW. Betaamyloid- induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neuroscience. 1994;63:517-531.
50. Abraham CR. Reactive astrocytes and alpha1- antichymotrypsin in Alzheimer's disease. Neurobiol Aging. 2001;22:931-936. (Pubitemid 34066561)
51. Bu G, Cam J, Zerbinatti C. LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci. 2006;1086:35-53.
52. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, Streb JW, Guo H, Rubio A, Van Nostrand W, Miano JM, Zlokovic BV. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2009;11:143-153.
53. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J. 2002; 21:5691-5700. (Pubitemid 35315269)
54. Yoon IS, Pietrzik CU, Kang DE, Koo EH. Sequences from the low density lipoprotein receptor-related protein (LRP) cytoplasmic domain enhance amyloid beta protein production via the beta-secretase pathway without altering amyloid precursor protein/LRP nuclear signaling. J Biol Chem. 2005;280:20140-20147. (Pubitemid 41379545)
55. Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the lowdensity lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci. 2004;24:4259-4265. (Pubitemid 38620802)
56. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, KounnasMZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest. 2000;106:1159-1166.
57. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13:1029-1031. (Pubitemid 47517512)